京新药业(002020) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was ¥3,335,970,889.11, representing a 2.39% increase compared to ¥3,258,075,481.25 in 2020[22] - The net profit attributable to shareholders for 2021 was ¥614,001,126.25, a decrease of 5.98% from ¥653,070,206.69 in 2020[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 15.49% to ¥515,377,939.98 in 2021 from ¥446,243,001.41 in 2020[22] - The net cash flow from operating activities decreased by 28.87% to ¥365,024,284.78 in 2021 from ¥513,210,535.56 in 2020[22] - The basic earnings per share for 2021 was ¥0.75, down 8.54% from ¥0.82 in 2020[22] - The total assets at the end of 2021 were ¥6,415,365,229.53, an increase of 13.22% from ¥5,666,246,990.95 at the end of 2020[22] - The weighted average return on net assets for 2021 was 14.37%, a decrease of 3.01 percentage points from 17.38% in 2020[22] - The company's operating income for the fourth quarter was ¥867,803,456.27, with a total annual operating income of ¥3,335,970,889.11, reflecting stable revenue generation[26] - The net profit attributable to shareholders for the fourth quarter was ¥184,791,060.33, showing a consistent increase throughout the year[26] - The net cash flow from operating activities in the fourth quarter reached ¥222,926,490.48, indicating strong cash generation capabilities[26] Assets and Investments - The net assets attributable to shareholders of the listed company increased to ¥4,817,411,307.25, representing a growth of 22.97% compared to ¥3,917,602,965.69 from the previous year[24] - The company reported a significant increase in R&D expenses, totaling ¥329,331,078.76, up 27.04% year-on-year, driven by ongoing innovative drug projects[94] - The company has a total of ¥343,887,358.83 in restricted assets, primarily due to guarantees for bank acceptance bills[115] - The total amount of raised funds used during the reporting period was ¥17,954.53 million, with a cumulative usage of ¥81,039.15 million[120] - The company has a significant focus on generic drug development, aiming to submit over 10 projects annually to strengthen its competitive edge[100] Research and Development - The company invested 329 million yuan in R&D in 2021, a 27% increase year-on-year, focusing on innovative drugs in the CNS and CV fields, with 11 innovative drug projects currently under research[63] - The company has received 29 new invention patents in 2021, bringing the total to 173 patents, including 121 invention patents, showcasing strong R&D capabilities[54] - The company is developing multiple new products, including a modified compound drug for hyperlipidemia and a new anti-epileptic drug, enhancing its product pipeline[100] - The number of R&D personnel rose to 488, an increase of 3.39% from 2020[101] - The company aims to enhance its innovative drug R&D capabilities, targeting the submission of 6 innovative drug applications and bulk R&D submissions for generic drugs in 2022[139] Market and Product Development - The company focuses on the fields of mental health and cardiovascular drugs, with key products including Rosuvastatin and Sertraline, aimed at treating high cholesterol and depression respectively[38] - The company has a diverse product pipeline covering CNS, cardiovascular, and digestive systems, with key products like Levetiracetam ranked first in the hospital market for anti-epileptic drugs[47] - The cardiovascular (CV) segment achieved annual sales revenue of 520 million yuan, with a year-on-year shipment increase of 14% for the CV pipeline[69] - The gastrointestinal (GI) segment reported sales revenue of 466 million yuan, a 15% increase year-on-year, with self-operated business revenue growing by 30%[69] - The company’s internet e-commerce sales exceeded 50 million yuan, marking a 378% year-on-year growth, becoming a new revenue and profit growth point[72] Corporate Governance and Management - The company has a total of nine board members, including three independent directors, ensuring compliance with legal requirements[155] - The company has implemented a transparent performance evaluation and incentive mechanism for its management personnel[159] - The company has a dedicated financial accounting department, ensuring independent financial decision-making and compliance with accounting regulations[170] - The company has a structured organization that operates separately from its controlling shareholder, with no interference in its operational activities[169] - The company actively engages with stakeholders to balance interests and promote sustainable development[160] Strategic Initiatives - The company plans to expand its marketing team to over 1,000 members in 2022 to support the launch of innovative drugs and new products[67] - The company is focusing on expanding its market presence in international mainstream markets, aiming to improve customer structure and increase market share in regions like Europe and North America[143] - The company is committed to enhancing its marketing capabilities through refined management and innovative business models[140] - The company plans to invest 200 million yuan in a new traditional Chinese medicine production base to enhance capacity and upgrade the industry structure[78] - The company has established several subsidiaries, including Hangzhou Jingzhe Biopharmaceutical Technology Co., Ltd. and BEACON & BIGTIDE USA, to enhance its operational capabilities[137] Financial Management - The company achieved a net increase in cash and cash equivalents of ¥626,806,159.85, reflecting a 33.42% increase year-on-year[106] - The company reported a decrease in cash flow from investment activities, with a net cash flow of ¥144,687,969.67, down 68.81% from the previous year[102] - The total remuneration paid to directors, supervisors, and senior management during the reporting period amounted to 11.7427 million yuan[194] - The chairman, Lü Gang, received a total pre-tax remuneration of 1.6884 million yuan[195] - The company has a unified compensation management system for non-independent directors, supervisors, and senior management based on performance evaluations[193]